Skip to main content
Equibles
CORT logo

CORT · Corcept Therapeutics Inc · Metrics

Track CORT — free

Use CORT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CORT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$87.26 -0.33 (-0.38%) Q2 2026 earnings call transcript
S&P 400 member Russell 1000 member Rebalance outlook locked
Market Cap
$9.47B
Shares
108.10M
Volume · Oct 28 343.81K Avg daily vol (3M) 1.23M

CORT metrics

99 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$87.59
Market cap
$9.47B

Price action

20 metrics
Price change (1W)
-24.8%
Price change (30D)
-24.2%
Price change (3M)
-7.0%
Price change (6M)
+87.9%
Price change (YTD)
+151.7%
Price change (1Y)
+20.7%
Trailing year
Price change (5Y)
+398.0%
52-week high
$123.57
52-week low
$32.15
Change from 52-week high
-29.1%
Change from 52-week low
+172.4%
Annualized volatility
83.2%
Annualized volatility (3M)
77.2%
Beta
1.9
RSI (14D)
26.7
Price vs SMA 50
-23.2%
Price vs SMA 200
+18.3%
Avg volume (3M)
1.23M
Relative volume
0.8
Average dollar volume
$136.94M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
108.10M

Valuation

12 metrics
P / E (TTM)
208.5
Trailing earnings · reciprocal yield 0.5%
PEG ratio
8.6
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
11.4×
reciprocal yield 8.8%
P / book
13.4
reciprocal yield 7.5%
FCF yield
1.1%
TTM · current market cap
Buyback yield
0.4%
P / FCF
88.6
reciprocal yield 1.1%
P / operating cash flow
86.3
reciprocal yield 1.2%
Earnings yield
0.6%

Historical valuation

8 metrics
P / E historical average (3Y)
64.2×
reciprocal yield 1.6%
P / E historical average (5Y)
50.6×
reciprocal yield 2.0%
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.4%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-03
Last earnings
2026-07-29

Profitability

9 metrics
Gross margin
98.3%
Operating margin
0.8%
Trailing 12 months
Net margin
6.6%
Gross profit (TTM)
$816.73M
Operating profit (TTM)
$6.41M
Net income (TTM)
$55.18M
Trailing 12 months
Diluted EPS (TTM)
$0.42
FCF margin
12.9%
Effective tax rate
-109.3%

Per share

11 metrics
Revenue per diluted share (TTM)
$7.16
Gross profit per diluted share (TTM)
$7.04
Operating profit per diluted share (TTM)
$0.00
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$0.43
Operating cash flow per diluted share (TTM)
$0.90
Free cash flow per diluted share (TTM)
$0.88
Capital expenditures per diluted share (TTM)
$0.02
R&D per diluted share (TTM)
$2.21
Stock compensation per diluted share (TTM)
$0.83
Book value per share
$6.11

Growth

11 metrics
Revenue growth YoY
+31.7%
Year over year
Net income growth YoY
+22.3%
Revenue (TTM)
$830.81M
Trailing 12 months
EPS growth YoY
+24.1%
Shares change YoY
-1.7%
Year over year · fewer shares
Revenue CAGR (3Y)
+23.7%
Revenue CAGR (5Y)
+16.6%
EPS CAGR (3Y)
-2.0%
EPS CAGR (5Y)
-0.7%
FCF CAGR (3Y)
+5.7%
FCF CAGR (5Y)
-1.2%

Quality

14 metrics
Return on equity
7.8%
Return on assets
6.2%
Debt / equity
—
Current ratio
2.9
EBITDA (TTM)
$8.08M
Free cash flow (TTM)
$106.92M
Quick ratio
2.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$111.04M
Total assets
$888.70M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$109.70M
Capital expenditures (TTM)
$2.78M
R&D (TTM)
$253.86M
SG&A (TTM)
$556.47M
Stock compensation (TTM)
$96.11M
R&D / revenue
30.6%
Stock compensation / revenue
11.6%

Ownership (13F)

9 metrics
13F filers
431
13F filer change QoQ
+78
Institutional ownership
78.1%
Conviction holders (share of 13F filers)
1.9%
Crowding (high-turnover and private-fund holders)
24.8%
Private-fund adviser ownership
23.3%
Active holders' share change QoQ
+3.5%
Holder tenure
16.9
Price vs estimated holder cost
+73.4%

Ownership (registered funds)

1 metrics
Index-fund ownership
24.0%

Short interest

3 metrics
Short interest
7.9%
Latest settlement · 12.3 days to cover
Days to cover
12.3d
Short-squeeze score
80 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$53.95M
Insider-sentiment score
19 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1088856 CUSIP 218352102 13F (30d) 116 filings 110 filers Visit website Investor relations